Back to top
more

FibroGen (FGEN)

(Real Time Quote from BATS)

$1.18 USD

1.18
902,043

-0.04 (-3.28%)

Updated May 10, 2024 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

by Zacks Equity Research

BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%

by Zacks Equity Research

Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

by Zacks Equity Research

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs

by Zacks Equity Research

Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.

FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD

by Zacks Equity Research

FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.

Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ

by Zacks Equity Research

Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ

What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Nitish Marwah headshot

5 Stocks with High Net Income Ratio to Grab Now

by Nitish Marwah

Investors always have a keen eye for companies having a high level of profitability regardless of the market condition.

Theravance Announces Positive Early Data on JAK Inhibitor

by Zacks Equity Research

Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.

Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)

by Zacks Equity Research

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Endo International Files BLA for Label Expansion of Xiaflex

by Zacks Equity Research

Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.

Radius (RDUS) Catches Eye: Stock Jumps 6.8%

by Zacks Equity Research

Radius (RDUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Ensign Group to Spin Off Home Health & Hospice Business

by Zacks Equity Research

Ensign Group (ENSG) to separate its home health and hospice business from the parent company.

FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

by Zacks Equity Research

AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.

Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta

by Zacks Equity Research

The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.

Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

by Zacks Equity Research

Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

Tilray (TLRY) Catches Eye: Stock Jumps 8.4%

by Zacks Equity Research

Tilray (TLRY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 357.14% and 492.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline

by Zacks Equity Research

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for FibroGen (FGEN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

by Zacks Equity Research

Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.

Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

by Zacks Equity Research

Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.